

Case report

Open Access

Radiation induced angiosarcoma a sequela of radiotherapy for breast cancer following conservative surgery

M Tahir*, P Hendry, L Baird, NA Qureshi, D Ritchie and P Whitford

Address: Department of Surgery, Crosshouse Hospital, Kilmarnock, UK

Email: M Tahir* - drtahirk@hotmail.com; P Hendry - paulhendry77@btinternet.com; L Baird - cottrell_lorna@yahoo.co.uk; NA Qureshi - drtahirk@hotmail.com; D Ritchie - Philippa.Whitford@aaaht.scot.nhs.uk; P Whitford - Philippa.Whitford@aaaht.scot.nhs.uk

* Corresponding author

Published: 11 September 2006

Received: 12 July 2006

International Seminars in Surgical Oncology 2006, **3**:26 doi:10.1186/1477-7800-3-26

Accepted: 11 September 2006

This article is available from: <http://www.issoonline.com/content/3/1/26>

© 2006 Tahir et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Radiation induced angiosarcomas (RIA) can affect breast cancer patients who had radiotherapy following conservative breast surgery. They are very rare tumors and often their diagnosis is delayed due to their benign appearance and difficulty in differentiation from radiation induced skin changes. Therefore it is very important that clinicians are aware of their existence. We report here a case of RIA followed by discussion and review of literature.

Background

Angiosarcomas are rare tumors of endovascular origin. Primary angiosarcomas account for only 0.04% of breast tumors. It affects a younger age group of 20–40 yrs. Secondary angiosarcoma can be induced by radiotherapy. Cases of radiation induced angiosarcoma (RIA) have been reported in women who had radiotherapy for breast cancer. RIA occurs in an older age group, with a mean age of 68 years [1]. It is difficult to diagnose due to its rarity, benign appearance and difficulty in differentiation from radiation induced changes in the skin [2].

We report a case of Angiosarcoma in a 78 years old woman. She had radiotherapy for breast cancer following conservative surgery and axillary node clearance.

Case report

Clinical history

In April 1996 this 78-year-old woman was diagnosed with a poorly differentiated lobular carcinoma in the upper outer part of the left breast. Clinically it measured 15 mm. She was treated with conservative breast surgery and level III axillary node clearance. Tumor margins were clear and

all lymph nodes were negative. Tamoxifen was commenced at 20 mg OD.

A course of postoperative radiotherapy was arranged due to breast conservation surgery. She received 46 Gy in 23 fractions over 35 days using paired glancing megavoltage fields. This treatment was completed in July 1996 and was followed by a boost to the site of excision of a further 12 Gy in 4 fractions over 7 days using 9MEV electrons. Chemotherapy was discussed but the patient did not want to pursue this option.

She remained in regular follow up with no evidence of local or regional recurrence. In June 2005 during a routine follow up appointment she reported a 2 cm area of purple skin lesion at the lower inner quadrant of the left breast (figure 1), with a history of it being there for about 3 months. It was associated with peau d'orange and soft tissue thickening extending from the lower inner quadrant across the midline. Mammography was not performed, as she was too tender. Ultrasound showed no evidence of a lesion deep to the abnormality. Freehand core biopsies were taken of the area. Pathology demonstrated the pres-



Figure 1
Radiation induced Angiosarcoma (left breast) following conservative surgery for breast cancer in a 78 years old lady.

ence of malignancy in keeping with high-grade angiosarcoma.

Staging investigations including CT chest and abdomen, CXR and bone scan none showed any evidence of metastasis. She had wide surgical excision and reconstruction with a Vertical Rectus Abdominus Myocutaneous flap (VRAM flap). She has completed her first year follow up without any recurrence.

Pathologic findings

Histological examination following routine processing and staining with haematoxylin and eosin shows malignant tumor (figure 2). Although this tumor is predominantly solid, comprising highly pleomorphic cells (figure




Figure 2
Histological sections from the biopsy at low power (4 × magnifications) show infiltration by a tumor with both solid areas and neoplastic vascular channels.

3) and areas with spindle cell morphology (figure 4) neoplastic vascular channels are also identified (figure 5). Immunohistochemical staining for CD31, CD34 and factor viii confirm endothelial differentiation both within the solid tumor component and the recognizable vascular channels. The possible differential diagnoses of carcinoma and malignant melanoma are excluded by the negativity of other stains (MNF and S100 respectively). The histological features are those of high grade angiosarcoma.

Histology from the original breast excision biopsy (figure 6) shows a lobular carcinoma, with strong oestrogen receptor positivity. This shows no similarity to the newly arising angiosarcoma.

Discussion and review of literature

Radiation induced sarcomas were first reported in literature in 1929[3] and the first case of sarcoma after radiotherapy for breast cancer was reported by Warren & Sommer in 1936[4]. Cahan et al [5] described the diagnostic criteria for Radiation induced sarcomas which include a previous history of radiotherapy with a latency period of several years (5 or more), development of sarcoma within a previous irradiated field and a histologic confirmation. This criterion was modified by Arlen et al [6] to include tissues adjacent to the radiated field and a shorter latency period of 3–4 years. Radiation induced angiosarcomas are characterized by their aggressive nature and most are high grade tumors [7,8]. They can develop after many years in women who have previously had radiotherapy for breast cancer.




Figure 3
At high power magnification (×40) there are highly pleomorphic cells with prominent nucleoli. Many mitotic figures are seen (arrows). Some individual apoptotic cells are also present.




Figure 4
This shows a high power view (x40 magnification) of an area with spindle cell morphology.

The etiology of radiation induced angiosarcomas in the breast remains controversial. Some investigators believe that many of the reported cases are actually metaplastic variants of the original Cancer [9,10]. Radiation induced metaplastic transformation is thought to be related to irreversible DNA damage [11]. Immunohistochemical stains of tumor tissue for factor VIII – related antigen & Ulex lectin stains are required to confirm the diagnosis of angiosarcoma and to differentiate it from the metaplastic recurrent breast cancer [7,8]. In our case we have performed these tests to confirm the diagnosis.




Figure 5
This high power view (x40 magnification) shows neoplastic vascular channels. These irregular channels interconnect and are lined by a single layer of highly atypical endothelial cells (see arrow).




Figure 6
At medium power (x20 magnification), histology from the original breast excision biopsy shows infiltrating strands of tumor cells with some pleomorphism. The tumor also forms circumscribed nodules.

Most cases of RIA occur in association with a total radiation dose in the range of 40–50 Gy [8,12]. It is difficult to analyze the relationship between the total radiation dose, individual fraction dose and the incidence of RIA, due to the rarity of cases in the literature and the difficulty in retrieving information many years after the primary treatment. A minimum total dose of 10 Gy in conventional doses per fraction appears necessary to result in RIA [13,14].

The incidence of RIA following radiotherapy to the breast varies from 0.05 to 0.2 % [15-17] with an average latency period reported as 12.5 years [18,19].

The presentation of RIA is often a cutaneous or subcutaneous lesion, painless, flat or nodular, bluish or purplish similar to benign angiomas, small hematomas or atypical telangiectasis [20,21]. Its diagnosis is often delayed by 8–12 months [8,11] due to a lack of specific symptoms and low suspicion following a long latency period after diagnosis of original tumor. Additional reasons cited for delayed diagnosis include difficulty in detecting the tumor in previously irradiated tissue and inadequate biopsies [2].

A high index of suspicion, careful patient evaluation and adequate biopsy tissue for pathologic diagnosis is mandatory. Mammography is typically negative in these cases [2] and diagnosis can be confirmed only by histopathological study of the biopsy. Cytology is generally misleading and not very informative [2].

There is general consensus in literature that the only logical treatment of RIA regardless of histologic type is wide surgical resection i.e. Mastectomy usually with a latis-

simus dorsi flap reconstruction. Conservative treatment even with negative margins exposes the patient to early recurrences and metastatic spread [2,17-20,22].

Adjuvant Chemotherapy in RIA has so far produced disappointing results [22].

Radiation therapy has been avoided in these cases secondary to concerns about the toxicity of repeated treatment. However recently some encouraging results have been achieved with the use of hyperfractionated radiotherapy [23].

Median survival in RIA is reported from 1.5 to 2.5 years [17]. Recurrence rates approach 70 % and 2-year disease free survival ranges from 0–35 % in various series [15,16].

Conclusion

This lesion is still rare, but with the increase in conservative breast surgery and radiotherapy, the incidence of RIA is likely to increase. Due to benign looking nature of the tumor in initial stages only a high index of suspicion and generous tissue biopsy can lead to early diagnosis. From review of the literature it is evident that early diagnosis and aggressive surgical approach can lead to a better prognosis. Chemotherapy has yet achieved no role in the treatment of these tumors but recently some encouraging results are seen with the use of Hyperfractionated radiotherapy and further work needs to be done in this regards.

Competing interests

The author(s) declare that they have no competing interests.

Acknowledgements

The pictures have also been submitted to "The Breast Journal Image section" for publication.

References

1. Stokkel MP, Peterse HL: **Angiosarcoma of the breast after lumpectomy and radiation therapy for adenocarcinoma.** *Cancer* 1992, **69**:2965-2968.
2. Bolin DJ, Lukas GM: **Low-grade dermal angiosarcoma of the breast following radiotherapy.** *Am Surg* 1996, **62**(8):668-72.
3. Martland HS: **Occupational poisoning in manufacture of luminous watch dials.** *JAMA* 1929, **92**:466-473.
4. Warren S, Sommer GN: **Fibrosarcoma of the soft parts with special reference to recurrence and metastasis.** *Arch Surg* 1936, **33**:425-450.
5. Cahan WG, Woodward HQ, Higinbotham NL, et al.: **Sarcoma arising in irradiated bone: report of eleven cases.** *Cancer* 1948, **1**:3-29.
6. Arlen M, Higinbotham NL, Huvos AG, et al.: **Radiation induced sarcoma of bone.** *Cancer* 1971, **28**:1087-1099.
7. Brady MS, Garfein CF, Petrek JA, et al.: **Post-treatment sarcoma in breast cancer patients.** *Ann Surg Oncol* 1994, **1**:66-72.
8. Souba WW, McKenna RJ Jr, Meis J, et al.: **Radiation induced sarcomas of the chest wall.** *Cancer* 1986, **57**:610-615.
9. Salm R: **The nature of so called post mastectomy lymphangiosarcoma.** *J Pathol Bacteriol* 1963, **85**:445-456.
10. Schaffer K, McKenzie CG, Salm R: **Post mastectomy lymphangiosarcoma: a reappraisal of the concept – a critical review and report of an illustrative case.** *Histopathology* 1979, **3**:131-152.
11. Little JB: **Cancer etiology: ionizing radiation.** In *Cancer Medicine* 4th edition. Edited by: Holland J, Frei E III, BAst RC. Baltimore, Md: Williams & Wilkins; 1997:293-306.
12. Pitcher ME, Davidson TI, Fisher C, et al.: **Post irradiation sarcoma of soft tissue and bone.** *Eur J Surg Oncol* 1994, **20**:63-56.
13. Tucker MA, D'Angio GJ, Boice JD Jr, et al.: **Bone sarcomas linked to radiotherapy and chemotherapy in children.** *N Engl J Med* 1987, **317**:588-593.
14. Woodard HQ: **Radiation Carcinogenesis in man: a critical review.** In *Environmental measurements lab*, 380 New York. NY: US Dept of Energy; 1980.
15. Strobbe LJ, Peterse HL, van Tinteren H, Wijnmaalen A, Rutgers EJTh: **Angiosarcoma of the breast after conservation therapy for invasive cancer, the incidence and outcome. An unforeseen sequela.** *Breast cancer Res Treat* 1998, **47**:101-109.
16. Marchal C, Weber B, de Lafontan B, et al.: **Nine breast Angiosarcomas after conservative treatment for breast carcinoma: a survey from French comprehensive cancer centers.** *Int J Radiat Oncol Biol Phys* 1999, **44**(1):113-119.
17. Givens SS, Ellerbrock NA, et al.: **Angiosarcoma arising in an irradiated breast. A case review of the literature.** *Cancer* 1989, **64**:2214-16.
18. Hunter TB, Martin PC, et al.: **Angiosarcoma of the breast. Two case reports and a review of the literature.** *Cancer* 1985, **56**:2099-106.
19. Fineberg S, Rosen PP: **Cutaneous Angiosarcoma and atypical vascular lesions of the skin and breast after radiation therapy for breast irradiation.** *Am J Clin Pathol* 1994, **102**:757-63.
20. Wijnmaalen A, Van Ooijen B, Van Geel BN, et al.: **Angiosarcoma of breast following Lumpectomy, axillary node dissection and radiotherapy for primary breast cancer: three case reports and a review of the literature.** *Int J Rad Oncol Biol Phys* 1993, **26**:135-9.
21. Rainwater LM, Martin JK, et al.: **Angiosarcoma of the breast.** *Arch Surg* 1986, **121**:699-72.
22. Slotman BJ, Van Hattum A, et al.: **Angiosarcoma of the breast following conservative treatment for breast cancer.** *Eur J Cancer* 1994, **30**:416-7.
23. Steven J, Feigenberg , et al.: **Angiosarcoma after breast-conserving therapy: Experience with Hyperfractionated radiotherapy.** *Int J Rad Oncol Biol Phys* 2002, **52**:620-626.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

